Marie Mazur, PharmD

Appointed in 2020, Marie provides leadership on the development and execution of Ready2Respond’s program goals and actions, while optimizing cross-sector partnerships to ensure cost-effective implementation of identified initiatives. Marie brings more than 20 years of experience in the vaccine industry. Prior to joining Ready2Respond, she headed up the Pandemic Response Solutions unit for Seqirus, a CSL Company. During her tenure, Seqirus became the global market leader in pandemic influenza vaccine response. In her prior role as President of the bioCSL unit, Marie led the commercial due diligence effort that resulted in the Novartis Influenza Business acquisition. Seqirus is now the only vaccine company focused on the prevention of seasonal and pandemic influenza.

In 2018-2019, Marie was Co-Chair of the Bio-Defense Policy Advisory Committee at the Biotechnology Innovation Organization. Prior to joining CSL, Marie held successive global commercial leadership positions at Sanofi Pasteur, 3M Pharmaceuticals and GlaxoSmithKline Biologicals, in Europe and in the United States. Marie received her doctorate in Pharmacy, and her master’s degree in Regulatory Affairs, from Paris University in France. She is also a graduate from INSEAD Business School.